New combo therapy offers hope for melanoma patients who failed standard treatment
NCT ID NCT02965716
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial studies a combination of two immunotherapy drugs—talimogene laherparepvec (T-VEC) and pembrolizumab—in 43 adults with advanced melanoma that has worsened despite prior anti-PD1/L1 therapy. T-VEC is a modified virus that infects and kills cancer cells while also stimulating the immune system, and pembrolizumab helps immune cells attack the tumor. The goal is to see if this combination can shrink tumors and control the disease in patients with limited options.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE III CUTANEOUS MELANOMA AJCC V7 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Allegiance Health
Jackson, Michigan, 49201, United States
-
CTCA at Western Regional Medical Center
Goodyear, Arizona, 85338, United States
-
Henry Ford Cancer Institute-Downriver
Brownstown, Michigan, 48183, United States
-
Henry Ford Hospital
Detroit, Michigan, 48202, United States
-
Henry Ford Macomb Hospital-Clinton Township
Clinton Township, Michigan, 48038, United States
-
Henry Ford West Bloomfield Hospital
West Bloomfield, Michigan, 48322, United States
-
Huntsman Cancer Institute/University of Utah
Salt Lake City, Utah, 84112, United States
-
Indiana University/Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, 46202, United States
-
Kansas City Veterans Affairs Medical Center
Kansas City, Missouri, 64128, United States
-
Keck Medical Center of USC Pasadena
Pasadena, California, 91105, United States
-
Los Angeles General Medical Center
Los Angeles, California, 90033, United States
-
Loyola University Medical Center
Maywood, Illinois, 60153, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, 90095, United States
-
USC / Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
-
University of Cincinnati Cancer Center-UC Medical Center
Cincinnati, Ohio, 45219, United States
-
University of Cincinnati Cancer Center-West Chester
West Chester, Ohio, 45069, United States
-
University of Kansas Hospital-Westwood Cancer Center
Westwood, Kansas, 66205, United States
-
University of South Alabama Mitchell Cancer Institute
Mobile, Alabama, 36688, United States
-
Vanderbilt University/Ingram Cancer Center
Nashville, Tennessee, 37232, United States